Assessment of Early-detection Based on Liquid Biopsy in Lung Cancer (ASCEND-LUNG)

March 24, 2021 updated by: Jun Wang, Peking University People's Hospital

Detection of Early-stage Lung Cancer Based on Liquid Biopsy of Peripheral Blood: a Prospective Study

The purpose of this study is to develop a lung cancer diagnosis tool using a multi-omics approach based on liquid biopsy.

Study Overview

Status

Recruiting

Conditions

Detailed Description

After being informed about the study and potential risks, all patients giving written informed consent will undergo a screening process to determine eligibility of study entry. Peripheral blood, tissue sample and imaging examinations of eligible patients will be collected for further analysis. Data collected will be used to develop a multi-omics lung cancer diagnosis model.

Study Type

Observational

Enrollment (Anticipated)

467

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Beijing
      • Beijing, Beijing, China, 100044
        • Recruiting
        • Peking University People's Hospital
        • Contact:
          • Chen Kezhong, M.D.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years to 74 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Newly diagnosed lung cancer patients between 40-75 years old, with solid nodule on CT imaging.

Description

Inclusion Criteria:

  • Signed informed consent
  • Male or female, age equal to or greater than 40 years old and less than 75 years old
  • Blood sample was collected before surgery for the detection of cfDNA methylation and other biomarkers
  • Lung cancer patients diagnosed for the first time within 42 days before blood sampling without any anti-tumor treatment; or patients who are highly suspected of lung cancer through imaging evaluation or other routine clinical diagnosis and confirmed by tissue biopsy or surgical specimens within 42 days after blood sampling
  • The subject has not received any local or systemic anti-tumor therapy before blood collection, including (not limited to) any surgery, local or systemic radiotherapy and chemotherapy, targeted therapy (including anti-angiogenesis), immunotherapy, cancer vaccines and hormone therapy, etc.

Exclusion Criteria:

  • Unable to obtain sufficient and qualified blood samples
  • Female subjects who are pregnant or breastfeeding
  • Patients who have received organ transplantation or non-autologous bone marrow or stem cell transplantation
  • Patients who have received blood transfusion within 7 days before blood sampling
  • Patients who have received anti-infection treatment within 14 days before blood collection
  • Patients who have receiving anti-tumor drugs for other diseases within 30 days before blood collection, such as methotrexate, cyclophosphamide, mercaptopurine, chlorambucil, tamoxifen, etc.
  • Patients who suffered from other malignant tumors or multiple primary tumors at the same time
  • Pathological confirmed benign lesions by tissue biopsy or surgery
  • Insufficient sample for a confirmed pathological diagnosis
  • Lung cancer patients with ground glass nodules on CT imaging.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Accuracy of the multi-omics early-stage lung cancer diagnosis model
Time Frame: through study completion, an average of 1.5 year
Sensitivity and specificity of the multi-omics early-stage lung cancer diagnosis model
through study completion, an average of 1.5 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Accuracy of diagnostic models established separately from multi-omics data
Time Frame: through study completion, an average of 1.5 year
Sensitivity and specificity models established separately from multi-omics data
through study completion, an average of 1.5 year
Relationship between multi-omics data
Time Frame: through study completion, an average of 1.5 year
Explore the relationship of features extracted from multi-omics data
through study completion, an average of 1.5 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Fan Yang, MD, Peking University People's Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 19, 2021

Primary Completion (Anticipated)

December 31, 2022

Study Completion (Anticipated)

December 31, 2024

Study Registration Dates

First Submitted

March 10, 2021

First Submitted That Met QC Criteria

March 24, 2021

First Posted (Actual)

March 25, 2021

Study Record Updates

Last Update Posted (Actual)

March 25, 2021

Last Update Submitted That Met QC Criteria

March 24, 2021

Last Verified

March 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe